Decipher Labs Ltd

Decipher Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.7.8 today, marking a significant decline amid ongoing market pressures and company-specific headwinds. The stock has underperformed its sector and broader indices, reflecting persistent challenges in its financial and operational metrics.

Decipher Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.8 today, marking a significant decline amid a sustained downward trend. The stock has been under pressure for several sessions, reflecting ongoing challenges in its financial performance and market positioning.

Decipher Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a fresh 52-week low of Rs.8.01 today, marking a significant decline amid ongoing downward momentum. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial and operational metrics.

Decipher Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a fresh 52-week low of Rs.8.99 today, marking a significant decline amid sustained downward momentum. The stock has underperformed its sector and broader market indices, reflecting ongoing financial pressures and subdued operational metrics.

Decipher Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 05 Sep 2024. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s performance and outlook.

Decipher Labs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation. This shift reflects changes across multiple analytical parameters, highlighting ongoing challenges in the company’s financial and operational performance.

Decipher Labs Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹10.00 crores, reported a return to profitability in Q2 FY26, posting a net profit of ₹0.02 crores after three consecutive quarters of losses. However, this marginal profit comes against a backdrop of severely declining revenues and deteriorating operational performance. The stock, trading at ₹10.10 as of November 14, has plummeted 34.84% over the past year, significantly underperforming both the benchmark Sensex and its sector peers.

Decipher Labs has reached a new 52-week low, continuing a six-day decline that has seen its stock price drop significantly. The company has faced substantial challenges, with a notable decrease in net sales and a negative profit after tax, reflecting ongoing financial difficulties and underperformance compared to its sector.

Decipher Labs has reached a new 52-week low, reflecting ongoing challenges in the Pharmaceuticals & Biotechnology sector. The company has experienced a significant decline in net sales and a negative profit after tax, alongside weak debt servicing capabilities, highlighting its difficult market position amid broader sector trends.

Decipher Labs has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company has reported negative results for four consecutive quarters, with a notable drop in net sales. Its financial metrics indicate ongoing challenges within the Pharmaceuticals & Biotechnology sector.

Decipher Labs has reached a new 52-week low, reflecting ongoing challenges as it reports negative results for four consecutive quarters. The company's performance has declined significantly over the past year, with trading below various moving averages and weak financial metrics, highlighting difficulties in the pharmaceuticals and biotechnology sector.